美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lakewood-Amedex Biotherapeutics (Direct Listing)

3.57

+1.7191.97%

成交量：7,232.51萬

成交額：3.44億

市值：625.16萬

市盈率：-0.40

高：6.85

開：6.50

低：3.29

收：1.86

52周最高：98.20

52周最低：1.66

股本：175.08萬

流通股本：57.99萬

量比：576.66

換手率：12472.15%

股息：- -

股息率：- -

每股收益(TTM):-8.9331

每股收益(LYR):-8.3987

淨資產收益率：--

總資產收益率：-507.36%

市淨率：-2.20

市盈率(LYR):-0.43

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Lakewood-Amedex Biotherapeutics (Direct Listing)

交易所：

NASDAQ

成立時間：

2006

員工人數：

5

公司地址：

8031 Cooper Creek Blvd.,Suite 103,University Park,Florida,United States

官網：

http://lakewoodamedex.com

郵編：

34201

電話：

傳真：

- -

簡介：

Lakewood-Amedex Biotherapeutics Inc.最初於2006年7月11日在特拉華州註冊成立。該公司是一家私營製藥公司，專註於通過開發其雙磷酸黴素來應對抗菌素耐藥性（AMR）的全球健康危機類抗菌劑。該公司的方法涉及一種新機制，旨在迅速破壞細菌膜的穩定性，這可能會降低耐藥性發展的可能性。他們的先導化合物Nu-3目前正處於治療感染的糖尿病足潰瘍的臨床試驗中，被配製為外用凝膠，可提供快速的抗菌作用和靶向遞送。除了糖尿病足潰瘍，該公司正在探索在治療複雜的尿路感染和肺部感染方面的應用。

董事

名稱

職位

Doug Manion

Chairman of the Board and Director

Kelvin Cooper

Chief Executive Officer,Director and SVP Research & Development

Joseph Tucker

Independent Director

Leonard J. DeRoma

Independent Director

股東

名稱

職位

Kelvin Cooper

Chief Executive Officer,Director and SVP Research & Development

Peter Ceccacci

Chief Financial Officer and VP Administration

Thomas Balzer

Chief Medical Officer and SVP Clinical Development

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/LABT/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":3.5707,"timestamp":1784737807104,"preClose":1.86,"halted":0,"volume":72325131,"delay":0,"changeRate":0.9197311827956988,"floatShares":579893,"shares":1750800,"eps":-8.933086,"marketStatus":"交易中","change":1.7107,"latestTime":"07-22 12:30:07 EDT","open":6.5,"high":6.85,"low":3.29,"amount":344075672.662326,"amplitude":1.913978,"askPrice":3.59,"askSize":117,"bidPrice":3.57,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-8.933086,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1784750400000},"marketStatusCode":2,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":1.86,"preHourTrading":{"tag":"盘前","latestPrice":6.5,"preClose":1.86,"latestTime":"09:29 EDT","volume":19505129,"amount":110730578.322742,"timestamp":1784726999977,"change":4.64,"changeRate":2.494624,"amplitude":3.215054},"postHourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.86,"latestTime":"19:51 EDT","volume":2744,"amount":4961.4973,"timestamp":1784677913783,"change":-0.02,"changeRate":-0.010753,"amplitude":0.05672},"volumeRatio":576.658314},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":579893,"roa":"-507.36%","roe":"--","lyrEps":-8.39872,"volumeRatio":576.658314,"shares":1750800,"dividePrice":0,"high":6.85,"amplitude":1.913978,"preClose":1.86,"low":3.29,"week52Low":1.66,"pbRate":"-2.20","week52High":98.2,"institutionHeld":0,"latestPrice":3.5707,"committee":0.438849,"eps":-8.933086,"divideRate":0,"volume":72325131,"delay":0,"ttmEps":-8.933086,"open":6.5,"prevYearClose":80,"prevWeekClose":1.89,"prevMonthClose":3.14,"prevQuarterClose":3.14,"fiveDayClose":2.43,"twentyDayClose":3.97,"sixtyDayClose":73.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-07-21","current":-0.432102,"percent":0.961538,"low":-12.282138,"twenty":-3.412052,"median":-2.486202,"eighty":-0.928674,"high":-0.62611,"avg":-3.52469,"sd":3.661131,"marketCap":2763829},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-21","current":-0.653185,"twenty":-3.412052,"median":-2.486202,"eighty":-0.928674,"marketCap":2763829}],"updateTime":1784733134200},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1977810588,"yearFounded":2006,"employeeNum":5,"address":"8031 Cooper Creek Blvd.,Suite 103,University Park,Florida,United States","zipCode":"34201","officePhone":"941 225 2515","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://lakewoodamedex.com","stockEarnings":[{"period":"1week","weight":-0.2706},{"period":"1month","weight":-0.5183},{"period":"3month","weight":-0.9768},{"period":"ytd","weight":-0.9768}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Lakewood-Amedex Biotherapeutics Inc.最初於2006年7月11日在特拉華州註冊成立。該公司是一家私營製藥公司，專註於通過開發其雙磷酸黴素來應對抗菌素耐藥性（AMR）的全球健康危機類抗菌劑。該公司的方法涉及一種新機制，旨在迅速破壞細菌膜的穩定性，這可能會降低耐藥性發展的可能性。他們的先導化合物Nu-3目前正處於治療感染的糖尿病足潰瘍的臨床試驗中，被配製為外用凝膠，可提供快速的抗菌作用和靶向遞送。除了糖尿病足潰瘍，該公司正在探索在治療複雜的尿路感染和肺部感染方面的應用。","exchange":"NASDAQ","name":"Lakewood-Amedex Biotherapeutics (Direct Listing)","nameEN":"Lakewood-Amedex Biotherapeutics (Direct Listing)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":{"directors":[{"name":"Doug Manion","position":"Chairman of the Board and Director"},{"name":"Kelvin Cooper","position":"Chief Executive Officer,Director and SVP Research & Development"},{"name":"Joseph Tucker","position":"Independent Director"},{"name":"Leonard J. DeRoma","position":"Independent Director"}],"executives":[{"name":"Kelvin Cooper","position":"Chief Executive Officer,Director and SVP Research & Development"},{"name":"Peter Ceccacci","position":"Chief Financial Officer and VP Administration"},{"name":"Thomas Balzer","position":"Chief Medical Officer and SVP Clinical Development"}]}}}